Dr. Mikkael Sekeres, Associate Professor of medicine and Director of the Leukemia Program at the Cleveland Clinic Tassig Cancer Center, will cover presenting characteristics of the MDS patient, Describe the most appropriate patient to receive hypomethylator therapy, and identify the most appropriate therapies for higher-risk MDS.